Immunoassay Developed for Quantitative Detection of Serum Interleukin‐6
|
By LabMedica International staff writers Posted on 07 Apr 2021 |

Image: The quantum dot (QD)‐based fluorescence lateral flow immunoassay (LFIA) strip can rapidly and accurately detect IL‐6 levels at different concentrations (Photo courtesy of University of South China)
Interleukin‐6 (IL‐6) is a multifunctional protein and is primarily produced by macrophages, monocytes, fibroblasts, and T lymphocytes, and plays important roles in immune regulation, hematopoiesis, inflammation, and tumorigenesis.
IL‐6 has shown the highest value in the diagnosis of sepsis compared with procalcitonin (PCT) and C‐reactive protein (CRP), which are also important biomarkers of infection. Traditional IL‐6 detection methods include chemiluminescence immunoassays (CLIA), enzyme‐linked immunosorbent assays (ELISA) and electrochemiluminescence immunoassays (ECLIA).
Medical Scientists at the Second Affiliated Hospital of University of South China (Hengyang, China) developed a quantum dot (QD)‐based fluorescence lateral flow immunoassay (LFIA) strip that can rapidly and accurately detect IL‐6 levels. The QD‐based LFIA strips were fabricated by conjugating cadmium selenide/zinc sulfide (CdSe/ZnS) QDs to the IL‐6 antibody. The strips were made of nitrocellulose (NC) membranes, semi‐rigid polyvinylchloride (PVC) sheets, and polyester fiber. The IL‐6 CLIA kits were from Beckman Coulter (Pasadena, CA, USA).
The fluorescence intensity of the test (T) line and the control (C) line on the strip were detected using the self‐designed KF‐Q001‐A fluorescence immunoassay analyzer (Kingfocus Biomedical Engineering Co., Ltd, Shenzhen City, China). The QDs and antibodies were dispensed onto the strip using a piece of three‐dimensional gold‐spraying equipment. IL‐6 CLIA detection was performed on the Beckman Coulter Dxl800 instrument. A total of 200 human serum samples were obtained from a local hospital, The IL‐6 concentrations of these samples ranged from 0 to 580.42 ng/mL. The samples were detected using the strip and the Beckman IL‐6 CLIA kit within two hours of each other.
The investigators reported that the test strip's linear range was 10–4,000 pg/mL, with a linear correlation coefficient of R2 ≥ 0.959. The sensitivity of the test strip was 1.995 pg/mL. The recovery rate was 95.72%–102.63%, indicating satisfying accuracy. The coefficient of variation (CV) of the intra‐assay was 2.148%–3.903%, while the inter‐assay was 2.412%–5.293%, verifying the strip's high precision. The cross‐reaction rates with various interleukins (IL‐1α, IL‐1β, IL‐2, IL‐4, and IL‐8) and interferon‐γ (IFN‐γ) were all less than 0.1%.
The authors concluded that they had successfully established a QD‐based LFIA method for rapid and accurate detection of human serum IL‐6, providing a more simple, robust, and economic point-of-care technology (POCT) for IL‐6 quantification, which is of great value for the early detection and treatment of sepsis and related disorders. The study was published on March 24, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Second Affiliated Hospital of University of South China
Beckman Coulter
Kingfocus Biomedical Engineering Co., Ltd
IL‐6 has shown the highest value in the diagnosis of sepsis compared with procalcitonin (PCT) and C‐reactive protein (CRP), which are also important biomarkers of infection. Traditional IL‐6 detection methods include chemiluminescence immunoassays (CLIA), enzyme‐linked immunosorbent assays (ELISA) and electrochemiluminescence immunoassays (ECLIA).
Medical Scientists at the Second Affiliated Hospital of University of South China (Hengyang, China) developed a quantum dot (QD)‐based fluorescence lateral flow immunoassay (LFIA) strip that can rapidly and accurately detect IL‐6 levels. The QD‐based LFIA strips were fabricated by conjugating cadmium selenide/zinc sulfide (CdSe/ZnS) QDs to the IL‐6 antibody. The strips were made of nitrocellulose (NC) membranes, semi‐rigid polyvinylchloride (PVC) sheets, and polyester fiber. The IL‐6 CLIA kits were from Beckman Coulter (Pasadena, CA, USA).
The fluorescence intensity of the test (T) line and the control (C) line on the strip were detected using the self‐designed KF‐Q001‐A fluorescence immunoassay analyzer (Kingfocus Biomedical Engineering Co., Ltd, Shenzhen City, China). The QDs and antibodies were dispensed onto the strip using a piece of three‐dimensional gold‐spraying equipment. IL‐6 CLIA detection was performed on the Beckman Coulter Dxl800 instrument. A total of 200 human serum samples were obtained from a local hospital, The IL‐6 concentrations of these samples ranged from 0 to 580.42 ng/mL. The samples were detected using the strip and the Beckman IL‐6 CLIA kit within two hours of each other.
The investigators reported that the test strip's linear range was 10–4,000 pg/mL, with a linear correlation coefficient of R2 ≥ 0.959. The sensitivity of the test strip was 1.995 pg/mL. The recovery rate was 95.72%–102.63%, indicating satisfying accuracy. The coefficient of variation (CV) of the intra‐assay was 2.148%–3.903%, while the inter‐assay was 2.412%–5.293%, verifying the strip's high precision. The cross‐reaction rates with various interleukins (IL‐1α, IL‐1β, IL‐2, IL‐4, and IL‐8) and interferon‐γ (IFN‐γ) were all less than 0.1%.
The authors concluded that they had successfully established a QD‐based LFIA method for rapid and accurate detection of human serum IL‐6, providing a more simple, robust, and economic point-of-care technology (POCT) for IL‐6 quantification, which is of great value for the early detection and treatment of sepsis and related disorders. The study was published on March 24, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Second Affiliated Hospital of University of South China
Beckman Coulter
Kingfocus Biomedical Engineering Co., Ltd
Latest Immunology News
- Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
- Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
- Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways
- Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel
- Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
- Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
- Compact Immunoanalyzer Gains CE Mark for Testing Across Local Care Settings
- COVID-19 and Flu Combo Test Launches With FDA Clearance
- Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
- Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
- Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
- Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
- Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
- FDA Approval Adds Automated Testing Option for Parvovirus B19 Serology
- Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier
- Blood-Based Immune Signal Could Reveal Lung Cancer Risk Before Tumors Develop
Channels
Clinical Chemistry
view channel
Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
Prostate cancer is the second leading cause of cancer-related death among men in the United States, with an estimated 333,830 new cases and 36,320 deaths this year, according to the American Cancer Society.... Read more
Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
Rheumatic heart disease (RHD) causes hundreds of thousands of deaths annually, disproportionately affecting children and young adults in low- and middle-income countries. Early detection remains challenging... Read moreMolecular Diagnostics
view channel
AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more
AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
Advances in molecular diagnostics are creating new opportunities to identify inherited diseases earlier, improve the classification of childhood cancers, and track infectious disease outbreaks affecting children.... Read more
Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
Tempus AI (Chicago, IL, USA) will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, taking place November 18–21 in Seoul, South Korea.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreMicrobiology
view channel
Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







